CartiFix
Product commercialization status – CartiFix
CartiFix regenerates normal hyaline cartilage and relieves the pain of arthritis.
Product commercialization status – CartiFix commercialization progress
CartiFix has showed cartilage regeneration in numerous preclinical tests and is currently undergoing IND assessment by the KFDA.
Product commercialization status – CartiFix Physical properties
CartiFix has been verified for its various properties that help in treating damaged joints.
High viscosity liquid material
Similar properties to hyaluronic acid. Applied cartifix protects cells and new cartilage from mechanical friction and external impact.
Resistance to proteolytic enzymes
It has excellent enzyme resistance compared to fibrin glue, which is currently the most widely used in cell transplantation. It can be used even in inflammatory environments with high enzyme concentration.
Various property control
Viscosity and decomposition rate can be adjusted depending on the molecular weight of hyaluronic acid.
Injectable properties
High viscosity at low shear (≤2.5) viscosity decreases at high shear (≥2.5). Injection is possible, and the high viscosity liquid is maintained again after injection.
Product commercialization status – CartiFix market
From micro-perforation to intra-articular injections, CartiFix is getting ready to expand into solutions for arthritis patients.
SOM
OP(Microfracture)
Global:
1.39B$
CAGR: 15.3%
SAM
OP(artificial joint)
Global:
9.73B$
CAGR: 3.40%
TAM
Intra-articular injections
Global:
2.19B$
CAGR: 5.0%